CytRx begins study into obesity gene
5th Sep 2005, 13:33 GMT
CytRx Corporation is to begin animal studies in an attempt to develop a new treatment for type-2 diabetes and obesity. In the study the company will use a technology known as "small interfering RNA" in order to suppress a gene known as RIP140.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol